Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of targeted therapies for cancers with high unmet medical needs. Headquartered in Redwood City, California, Oncternal was originally formed in 2017 as an independent entity and subsequently rebranded from Verastem Oncology in 2020. The company’s research and development efforts center on small-molecule inhibitors designed to modulate key signaling pathways involved in tumor growth and immune evasion.
The company’s pipeline includes several advanced clinical-stage candidates. Momelotinib, a JAK1/JAK2 and ACVR1 inhibitor, is being investigated for the treatment of myelofibrosis with an ongoing Phase 3 study. Defactinib, a FAK inhibitor, is in Phase 2 trials for KRAS-mutant solid tumors, including non-small cell lung and pancreatic cancers. Oncternal has also advanced ONCT-380, a novel BTK inhibitor targeting C481S-mutant forms of the enzyme in B-cell malignancies, and ONCT-534, a menin inhibitor for acute leukemias, into early-stage development.
Oncternal’s clinical programs are conducted across a global network of trial sites in North America, Europe and the Asia-Pacific region. The company collaborates with leading academic institutions and contract manufacturing organizations to support the production and distribution of its drug candidates. Strategic partnerships and regulatory engagements are central to Oncternal’s approach to facilitate potential commercialization in key markets worldwide.
The company is led by President and Chief Executive Officer Jeffrey Cleland, who brings more than two decades of experience in oncology drug development, and is supported by a management team comprised of seasoned industry executives and scientific advisors. Under this leadership, Oncternal is advancing its targeted therapy platform with the goal of delivering novel treatment options to patients facing limited therapeutic choices.
AI Generated. May Contain Errors.
